Literature DB >> 21376584

2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure-activity relationship study.

Qianyi Chen1, Vashti C Bryant, Hernando Lopez, David L Kelly, Xu Luo, Amarnath Natarajan.   

Abstract

The quinoxaline core is considered a privileged scaffold as it is found in a variety of biologically relevant molecules. Here we report the synthesis of a quinoxalin-6-amine library, screening against a panel of cancer cell lines and a structure-activity relationship (SAR). This resulted in the identification of a bisfuranylquinoxalineurea analog (7c) that has low micromolar potency against the panel of cancer cell lines. We also show that cells treated with quinoxalineurea 7c results in caspase 3/7 activation, PARP cleavage and Mcl-1 dependent apoptosis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376584      PMCID: PMC3063321          DOI: 10.1016/j.bmcl.2011.02.055

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

1.  Synthesis and biological activities of pyrazolo[3,4-g]quinoxaline derivatives.

Authors:  Laurent Gavara; Emmanuelle Saugues; Georges Alves; Eric Debiton; Fabrice Anizon; Pascale Moreau
Journal:  Eur J Med Chem       Date:  2010-09-15       Impact factor: 6.514

2.  Synthesis and peptidyl-prolyl isomerase inhibitory activity of quinoxalines as ligands of cyclophilin A.

Authors:  Feng Wang; Jing Chen; Xuejun Liu; Xu Shen; Xuchang He; Hualiang Jiang; Donglu Bai
Journal:  Chem Pharm Bull (Tokyo)       Date:  2006-03       Impact factor: 1.645

3.  Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage.

Authors:  Hernando Lopez; Liqiang Zhang; Nicholas M George; Xiaoqiong Liu; Xiaming Pang; Jacquelynn J D Evans; Natalie M Targy; Xu Luo
Journal:  J Biol Chem       Date:  2010-03-11       Impact factor: 5.157

Review 4.  A synopsis of recent developments in antiglaucoma drugs.

Authors:  M A McLaughlin; G C Chiou
Journal:  J Ocul Pharmacol       Date:  1985

Review 5.  Privileged scaffolds for library design and drug discovery.

Authors:  Matthew E Welsch; Scott A Snyder; Brent R Stockwell
Journal:  Curr Opin Chem Biol       Date:  2010-03-18       Impact factor: 8.822

6.  Synthesis and antitumor activities of a series of novel quinoxalinhydrazides.

Authors:  Fedora Grande; Francesca Aiello; Osvaldo De Grazia; Antonella Brizzi; Antonio Garofalo; Nouri Neamati
Journal:  Bioorg Med Chem       Date:  2006-10-05       Impact factor: 3.641

7.  Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.

Authors:  Anton Simeonov; Adam Yasgar; Ajit Jadhav; G L Lokesh; Carleen Klumpp; Sam Michael; Christopher P Austin; Amarnath Natarajan; James Inglese
Journal:  Anal Biochem       Date:  2007-12-05       Impact factor: 3.365

8.  Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.

Authors:  Paul A Johnston; Caleb A Foster; Marni Brisson Tierno; Tong Ying Shun; Sunita N Shinde; William D Paquette; Kay M Brummond; Peter Wipf; John S Lazo
Journal:  Assay Drug Dev Technol       Date:  2009-06       Impact factor: 1.738

9.  Fluorescence-enhanced europium-diethylenetriaminepentaacetic (DTPA)-monoamide complexes for the assessment of renal function.

Authors:  Lori K Chinen; Karen P Galen; K T Kuan; Mary E Dyszlewski; Hiroaki Ozaki; Hiroaki Sawai; Raghootama S Pandurangi; Frederick G Jacobs; Richard B Dorshow; Raghavan Rajagopalan
Journal:  J Med Chem       Date:  2008-02-06       Impact factor: 7.446

10.  One novel quinoxaline derivative as a potent human cyclophilin A inhibitor shows highly inhibitory activity against mouse spleen cell proliferation.

Authors:  Jian Li; Jing Chen; Li Zhang; Feng Wang; Chunshan Gui; Li Zhang; Yu Qin; Qiang Xu; Hong Liu; Fajun Nan; Jingkang Shen; Donglu Bai; Kaixian Chen; Xu Shen; Hualiang Jiang
Journal:  Bioorg Med Chem       Date:  2006-05-06       Impact factor: 3.641

View more
  14 in total

1.  A quinoxaline urea analog uncouples inflammatory and pro-survival functions of IKKβ.

Authors:  Dulce Maroni; Sandeep Rana; Chandrani Mukhopadhyay; Amarnath Natarajan; Mayumi Naramura
Journal:  Immunol Lett       Date:  2015-10-27       Impact factor: 3.685

2.  Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.

Authors:  Rajkumar Rajule; Vashti C Bryant; Hernando Lopez; Xu Luo; Amarnath Natarajan
Journal:  Bioorg Med Chem       Date:  2012-02-16       Impact factor: 3.641

3.  Targeting acetyl-CoA metabolism attenuates the formation of fear memories through reduced activity-dependent histone acetylation.

Authors:  Desi C Alexander; Tanya Corman; Mariel Mendoza; Andrew Glass; Tal Belity; Ranran Wu; Rianne R Campbell; Joseph Han; Ashley A Keiser; Jeffrey Winkler; Marcelo A Wood; Thomas Kim; Benjamin A Garcia; Hagit Cohen; Philipp Mews; Gabor Egervari; Shelley L Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-03       Impact factor: 12.779

4.  Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.

Authors:  Prakash Radhakrishnan; Vashti C Bryant; Elizabeth C Blowers; Rajkumar N Rajule; Nagsen Gautam; Muhammad M Anwar; Ashley M Mohr; Paul M Grandgenett; Stephanie K Bunt; Jamie L Arnst; Subodh M Lele; Yazen Alnouti; Michael A Hollingsworth; Amarnath Natarajan
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

5.  Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.

Authors:  Nagendra K Chaturvedi; Rajkumar N Rajule; Ashima Shukla; Prakash Radhakrishnan; Gordon L Todd; Amarnath Natarajan; Julie M Vose; Shantaram S Joshi
Journal:  Mol Cancer Ther       Date:  2013-08-20       Impact factor: 6.261

6.  In Vitro and In Vivo Activities of 2,3-Diarylsubstituted Quinoxaline Derivatives against Leishmania amazonensis.

Authors:  Vanessa Kaplum; Juliana Cogo; Diego Pereira Sangi; Tânia Ueda-Nakamura; Arlene Gonçalves Corrêa; Celso Vataru Nakamura
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

7.  Isatin Derived Spirocyclic Analogues with α-Methylene-γ-butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study.

Authors:  Sandeep Rana; Elizabeth C Blowers; Calvin Tebbe; Jacob I Contreras; Prakash Radhakrishnan; Smitha Kizhake; Tian Zhou; Rajkumar N Rajule; Jamie L Arnst; Adnan R Munkarah; Ramandeep Rattan; Amarnath Natarajan
Journal:  J Med Chem       Date:  2016-04-26       Impact factor: 7.446

8.  Small molecule binding to inhibitor of nuclear factor kappa-B kinase subunit beta in an ATP non-competitive manner.

Authors:  John V Napoleon; Sarbjit Singh; Sandeep Rana; Mourad Bendjennat; Vikas Kumar; Smitha Kizhake; Nicholas Y Palermo; Michel M Ouellette; Tom Huxford; Amarnath Natarajan
Journal:  Chem Commun (Camb)       Date:  2021-05-11       Impact factor: 6.222

9.  Cyclophilin J PPIase Inhibitors Derived from 2,3-Quinoxaline-6 Amine Exhibit Antitumor Activity.

Authors:  Xuemei Zhao; Chengcai Xia; Xiaodan Wang; Hao Wang; Ming Xin; Long Yu; Yulong Liang
Journal:  Front Pharmacol       Date:  2018-02-21       Impact factor: 5.810

10.  Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy.

Authors:  Satish Sagar; Sarbjit Singh; Jayapal Reddy Mallareddy; Yogesh A Sonawane; John V Napoleon; Sandeep Rana; Jacob I Contreras; Christabelle Rajesh; Edward L Ezell; Smitha Kizhake; Jered C Garrison; Prakash Radhakrishnan; Amarnath Natarajan
Journal:  Eur J Med Chem       Date:  2021-05-30       Impact factor: 7.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.